Patent Number: 6,309,873

Title: Streptokinase mutants

Abstract: The present invention is related to the field of biotechnology and genetic engineering techniques, particularly to a method for obtaining mutants obtain from streptokinase, to the molecules obtained from this method, as well as the expression vectors and microorganisms for recombinant obtaining. The object of the present invention is to achieve streptokinase mutants from modifications of skc-2 gene coding for streptokinase SKC-2 (Heberkinase.RTM.), such that the obtained mutants conserve their capacity for plasminogen activator complex formation having reduced antigenicity, that could constitute preferred alternatives to native streptokinase for thrombolytic therapy. The molecules obtained from present invention can be used in the treatment of disorders as myocardial infarct, pulmonary thromboembolism, surgical complications and other cases of thrombosis.

Inventors: Torrens Madrazo; Isis del Carmen (Habana, CU), Fuente Garcia; Jose de la (Habana, CU), Ojalvo; Ariana Garcia (Habana, CU), Menendez; Alina Seralena (Habana, CU), Escalona; Elder Pupo (Habana, CU), Masso; Julio Raul Fernandez (Habana, CU), Gonzalez Griego; Martha de Jesus (Habana, CU)

Assignee: Centro de Ingenieria Genetica y Biotechnologia

International Classification: C07K 14/195 (20060101); C07K 14/315 (20060101); A61K 38/00 (20060101); A61K 39/00 (20060101); C12N 001/20 (); C12N 009/70 (); C12N 015/00 (); C12P 021/06 ()

Expiration Date: 10/30/2018